1Ashcroft DM,Dimmock P,Garside R,et al.Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis:meta-analysis of randomised controlled trials[J].BMJ,2005,330(7490):516.
2Patel RR,Vander Straten MR,Korman NJ.The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis[J].Arch Dermatol,2003,139(9):1184-1186.
3Niwa Y,Terashima T,Sumi H.Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin[J].Br J Dermatol,2003,149(5):960-967.
4Becker JC,Houben R,Vetter CS,et al.The carcinogenic potential of tacrolimus ointment beyond immune suppression:a hypothesis creating case report[J].BMC Cancer,2006,6:7.
5US Food and Drug Administration.FDA Public Health Advisory:Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment[EB/OL].[2005-03-10].Available http://www.fda.gov/medwatch//SAFETY/2005/safety05.htm#Elidel.
6Kempers S,Boguniewicz M,Carter E,et al.A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis[J].J Am Acad Dermatol,2004,51(4):515-525.
7Antaya R,Paller A,Duarte A.Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in patients with atopic dermatitis[poster].30th Annual Meeting of the Society for Pediatric Dermatology,June 17-20,2004[C].Charleston:[s.n.],c2004.
8Grundmann-Kollmann M,Podda M,Ochsendorf F,et al.Mycophenolate mofetil is efective in the treatment of atopic dermatitis[J].Arch Dermato1,2001,137(7):870-873.0.
9Benez A,Fierlbeck G.Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil[J].Br J Dermatol,2001,144(3):638-639.
10Hartmann M,Enk A.Mycophenolate mofetil and skin diseases[J].Lupus,2005,14 (Suppl 1):S58-63.
